Načítá se...
Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?
Despite several clinical trials have assessed different agents in the adjuvant setting, renal cell carcinoma (RCC) still remains a disease orphan of an effective adjuvant treatment. In fact, systemic therapies targeting angiogenesis that have been observed to be effective in metastatic setting faile...
Uloženo v:
| Vydáno v: | Transl Androl Urol |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8039625/ https://ncbi.nlm.nih.gov/pubmed/33850792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tau-20-1125 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|